Late-stage clinical biopharmaceutical company, X4 Pharmaceuticals, is dedicated to the development and commercialization of innovative therapeutics aimed at treating rare diseases. The company's primary focus is on mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4). Currently, the promising drug candidate is in Phase III clinical trial for the treatment of a wide range of ailments, including warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as receiving Phase Ib clinical trial for the treatment of chronic neutropenia and Waldenström macroglobulinemia. X4 Pharmaceuticals is also actively developing X4P-002 and X4P-003, two CXCR4 antagonists aimed at treating brain cancers and CXCR4 disorders and primary immunodeficiencies, respectively. The company has established a licensing agreement with Abbisko Therapeutics Co. Ltd., which will allow Abbisko to develop, manufacture, and market mavorixafor combined with checkpoint inhibitors or other agents to treat various oncology indications. Headquartered in Boston, Massachusetts, X4 Pharmaceuticals is quickly establishing itself as a leader in researching and developing vital, life-saving therapeutics.
X4 Pharmaceuticals's ticker is XFOR
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at X4 Pharmaceuticals
It is x4pharma.com
X4 Pharmaceuticals is in the Healthcare sector
X4 Pharmaceuticals is in the Biotechnology industry
The following five companies are X4 Pharmaceuticals's industry peers: